PEG10 Biomarker Detection for ALS Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) lack reliable biomarkers and effective therapeutic options, with limited understanding of the molecular mechanisms underlying the disease, leading to ineffective symptom management and lack of significant lifespan prolongation.
Innovation Solution
Detection and assessment of PEG10 levels and activity in biological samples, which accumulate due to UBQLN2 dysfunction, serving as a novel biomarker for ALS diagnosis and treatment prediction, using methods such as Western blot, ELISA, and immunohistochemistry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current ALS treatments (Riluzole and Edaravone) are used to inhibit excitotoxicity and oxidative stress, then some symptom management is achieved, but therapeutic success is limited and lifespan is not significantly prolonged
Solution Approach 1:
The patent introduces PEG10 as an intermediary biomarker that mediates between UBQLN2 dysfunction and ALS pathology. By detecting PEG10 levels, the invention enables early intervention before full disease manifestation, potentially improving therapeutic outcomes and lifespan through timely treatment initiation rather than relying on existing treatments that show limited efficacy.
Solution Approach 2:
The invention changes the diagnostic parameter from clinical symptoms to molecular biomarkers (PEG10 protein levels). This parameter change enables earlier detection and intervention, allowing treatment to begin before irreversible neuronal damage occurs, thereby potentially improving both therapeutic success and lifespan outcomes.
2Loss of information
If multiple genetic mutations are identified as risk factors for familial ALS, then understanding of disease etiology improves, but treatment options remain limited as they target downstream effects shared among familial and sporadic ALS
Solution Approach 1:
The patent extracts the common downstream effect (PEG10 accumulation) from the diverse genetic causes of ALS. Regardless of whether ALS is familial or sporadic, PEG10 accumulates as a result of UBQLN2 dysfunction, providing a universal biomarker and potential treatment target that is independent of specific genetic mutations.
Solution Approach 2:
PEG10 serves as a universal biomarker across different ALS subtypes (familial and sporadic). The invention makes the treatment approach universal by targeting the common pathway of PEG10 accumulation rather than treating each genetic mutation separately, thereby expanding treatment versatility despite the heterogeneity of ALS etiology.
3Ease of operation
If existing ALS treatments alter generalized neuronal function to address symptoms, then symptom management is achieved, but side effects increase due to lack of specificity
Solution Approach 1:
The patent applies local quality by targeting a specific molecular pathway (PEG10/UBQLN2) rather than altering generalized neuronal function. This localized approach addresses the specific pathology of ALS without the broad side effects associated with non-specific treatments, as the intervention is directed at the particular protein accumulation process rather than general neuronal activity.
Data Source
AI summary
The current invention includes novel methods and compositions for the detection of novel biomarkers of ALS.